C/CPublished research associates this genotype with typical VKORC1 expression and standard warfarin dosing requirements.
C/TPublished research associates this genotype with reduced VKORC1 expression, associated with needing a lower-than-average warfarin dose to reach the same anticoagulation effect.
T/TPublished research associates this genotype with substantially reduced VKORC1 expression, associated with needing a markedly lower warfarin dose. Starting at a standard dose without accounting for this genotype is associated with elevated bleeding risk during the initial treatment period.
This is a pharmacogenomic finding with clinical dosing guidelines (CPIC). If you are prescribed warfarin, share this result with your doctor — dosing algorithms that incorporate VKORC1 (and CYP2C9) genotype are standard practice. Do not adjust any medication on your own.
Source: Rieder et al. 2005, New England Journal of Medicine — effect of VKORC1 haplotypes on transcription and warfarin dose.